Your browser doesn't support javascript.
loading
Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer.
Kumari, Leena; Ehsan, Iman; Mondal, Arunima; Al Hoque, Ashique; Mukherjee, Biswajit; Choudhury, Pritha; Sengupta, Arunima; Sen, Ramkrishna; Ghosh, Prasanta.
Afiliación
  • Kumari L; Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
  • Ehsan I; Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
  • Mondal A; Department of Life Science and Biotechnology, Jadavpur University, Kolkata, India.
  • Al Hoque A; Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
  • Mukherjee B; Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
  • Choudhury P; Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Ohio, USA.
  • Sengupta A; Department of Life Science and Biotechnology, Jadavpur University, Kolkata, India.
  • Sen R; Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
  • Ghosh P; Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India.
J Drug Target ; 31(5): 521-536, 2023 06.
Article en En | MEDLINE | ID: mdl-37010248
Non-small cell lung cancer (NSCLC) is one of the most prevalent cancers diagnosed worldwide, yet managing it is still challenging. The epidermal growth factor receptor (EGFR) exhibits aberrant signalling in a wide range of human cancers, and it is reported to overexpress in most NSCLC cases. The monoclonal antibody [Cetuximab (Cet)] was conjugated onto the surface of the poly (lactide-co-glycolide) (PLGA) nanoparticles which were loaded with docetaxel (DTX) for the development of targeted therapy against lung cancer. This site-specific delivery system exhibited an enhanced cellular uptake in lung cancer cells which overexpress EGFR (A549 and NCI-H23). The nanoparticles also showed better therapeutic effectiveness against NSCLC cells, as evidenced by reduced IC50 values, cell cycle arrest at the G2/M phase, and increased apoptosis. The improved efficacy and in vivo tolerance of Cet-DTX NPs were demonstrated in benzo(a)pyrene (BaP)-induced lung cancer mice model. Histopathological analysis showed that intravenous injection of Cet-DTX NP to mice carrying lung cancer greatly reduced tumour development and proliferation. Comparing Cet-DTX NP to free drug and unconjugated nanoparticles, it also had negligible side effects and improved survival rates. Therefore, Cet-DTX NPs present a promising active targeting carrier for lung tumour-NSCLC-selective treatment.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Nanopartículas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Drug Target Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Nanopartículas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Observational_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Drug Target Asunto de la revista: FARMACOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: Reino Unido